Prenetics Global (NASDAQ:PRE – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Institutional and Insider Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Prenetics Global and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -60.70% | -30.12% | -23.87% |
| Neuphoria Therapeutics | N/A | -53.17% | -36.15% |
Volatility and Risk
Valuation & Earnings
This table compares Prenetics Global and Neuphoria Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $30.62 million | 8.64 | -$46.30 million | ($2.03) | -7.74 |
| Neuphoria Therapeutics | $15.65 million | 1.41 | -$370,000.00 | ($4.88) | -0.84 |
Neuphoria Therapeutics has lower revenue, but higher earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Prenetics Global and Neuphoria Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 1 | 0 | 1 | 0 | 2.00 |
| Neuphoria Therapeutics | 2 | 0 | 2 | 0 | 2.00 |
Prenetics Global currently has a consensus target price of $32.00, indicating a potential upside of 103.56%. Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 410.95%. Given Neuphoria Therapeutics’ higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Prenetics Global.
Summary
Prenetics Global beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
